Please login to the form below

Not currently logged in
Email:
Password:

ADA

This page shows the latest ADA news and features for those working in and with pharma, biotech and healthcare.

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

The researchers identified improvement in scores on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) and the 13-item cognitive subscale of the AD Assessment Scale (ADAS-Cog13), although

Latest news

More from news
Approximately 17 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    GlaxoSmithKline (GSK) launched its gene therapy STRIMVELIS, a one dose treatment for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), in Europe in 2016 with an outcomes-based annuity

  • The fight for affordable insulin The fight for affordable insulin

    The movement is also distancing itself from some of the big type 1 diabetes advocacy organisations, such as the American Diabetes Association (ADA) and the Juvenile Diabetes Foundation (JDF), which it

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    Ada is an artificial intelligence (AI) app that helps patients navigate quickly and accurately to the right health service and, ultimately, the right diagnosis. ... So far, Ada has performed eight million assessments around the globe, and every three

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    GSK’s Strimvelis for ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency) followed in 2016, and was a similar commercial failure.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    pancreatitis. Then GSK’s Strimvelis followed in 2016 for a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency).

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and impressive R&D pipeline to apply the approach

  • Cello Health boosts senior leadership team Cello Health boosts senior leadership team

    He previously served as managing director at Medicom International, an international healthcare publishing firm as well as ADA holdings and ICI Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics